| 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] | Technology appraisal guidance |
| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064] | Technology appraisal guidance |
| AI and novel technologies in lung function measurement | Health technology evaluation |
| Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] | Technology appraisal guidance |
| Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036] | Technology appraisal guidance |
| Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Technology appraisal guidance |
| Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471] | Technology appraisal guidance |
| Apraglutide for treating short bowel syndrome
[ID6533] | Technology appraisal guidance |
| Aprocitentan for treating resistant hypertension [TSID10395] | Technology appraisal guidance |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | Medical technologies guidance |
| Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure: Early Value Assessment | Health technology evaluation |
| Artificial intelligence technologies for mammography: early value assessment | Health technology evaluation |
| Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease
[ID6524] | Technology appraisal guidance |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894] | Technology appraisal guidance |
| Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515] | Technology appraisal guidance |
| Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401] | Technology appraisal guidance |
| Balloon cryoablation for Barrett's oesophagus | Interventional procedures guidance |
| Baloxavir marboxil for Influenza | Technology appraisal guidance |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] | Technology appraisal guidance |